Abstract：
National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies evaluate the value of vaccines and provide decision-making authorities with recommendations. The availability of information on disease-burden evidence considered or required for the assessment of vaccines included in national immunization programs (NIPs) is limited. The aim of this review is to summarize the epidemiologic and health economic (HE) evidence considered by NITAGs/HTA agencies when evaluating pediatric pneumococcal conjugate vaccine (PCV) NIPs. A systematic literature review of national recommendation reports for PCV NIPs in children in 31 European countries, published since 2001, was performed using NITAG/HTA agency websites, Google, MEDLINE, and EMBASE. The presence of epidemiological data was mapped, HE data was extracted, and findings were summarized. A total of 46 records for 19 countries were identified. Fifteen countries\' records included a recommendation concerning implementation of PCV NIP, switching from one PCV to another or a change in vaccination schedule within an existing NIP. All of these included epidemiological invasive pneumococcal disease data, and to varying degree epidemiological data on acute otitis media and pneumonia. HE data was referenced in 13 countries\' records, with 8 countries providing in-depth details on cost-effectiveness analyses. Pediatric PCV NIP recommendations were published by 61% of European countries, with varying degree of details and decision rationale. Some countries only publish the HE aspect of their rationale. The identified material can provide insight and support local policymakers and clinicians how data influenced the decision-making process in their countries.
摘要：
国家免疫技术咨询组（NITAG）和卫生技术评估（HTA）机构评估疫苗的价值，并向决策机构提供建议。评估国家免疫计划（NIP）中包括的疫苗所考虑或需要的疾病负担证据的信息的可用性有限。这篇综述的目的是总结NITAG/HTA机构在评估小儿肺炎球菌结合疫苗（PCV）NIP时考虑的流行病学和健康经济学（HE）证据。对31个欧洲国家儿童PCVNIP的国家推荐报告进行了系统的文献综述，自2001年以来发布，使用NITAG/HTA机构网站进行，Google,MEDLINE,和EMBASE。绘制了流行病学数据的存在，提取了HE数据，并对研究结果进行了总结。共确定了19个国家的46条记录。15个国家的记录包括一项关于实施PCVNIP的建议，从一种PCV切换到另一种PCV，或在现有的NIP中改变疫苗接种时间表。所有这些都包括流行病学侵袭性肺炎球菌疾病数据，以及不同程度的急性中耳炎和肺炎的流行病学数据。HE数据在13个国家/地区的记录中引用，8个国家提供了关于成本效益分析的深入细节。61％的欧洲国家发布了儿科PCVNIP建议，具有不同程度的细节和决策理由。一些国家只公布其理由的HE方面。确定的材料可以提供洞察力，并支持当地政策制定者和临床医生数据如何影响其国家的决策过程。
